Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
St. Paul, MN
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
St. Paul, MN
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Santa Fe, NM
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Santa Fe, NM
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Bronx, NY
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Poughkeepsie, NY
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Asheville, NC
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Charlotte, NC
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Statesville, NC
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Statesville, NC
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Portland, OR
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Portland, OR
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Providence, RI
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Providence, RI
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Houston, TX
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Houston, TX
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
mi
from
Adelaide,
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
mi
from
Adelaide,
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Nashville, TN
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated:  2/8/2017
Clinical Research Facility
mi
from
Seattle, WA
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
Status: Enrolling
Updated: 2/8/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Downey, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Downey, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Pasadena, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
San Francisco, CA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Honolulu, HI
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Boston, MA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Lincoln, NE
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
mi
from
Cedar Creek, TX
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
mi
from
Cedar Creek, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Clinical Research Facility
mi
from
Seattle, WA
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated:  2/16/2017
Site Reference ID/Investigator# 133172
mi
from
Concord,
Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B
Status: Enrolling
Updated: 2/16/2017
Site Reference ID/Investigator# 133172
mi
from
Concord,
Click here to add this to my saved trials
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Status: Enrolling
Updated:  2/22/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
Status: Enrolling
Updated: 2/22/2017
Brooke Army Medical Center
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
University of California at San Francisco
mi
from
San Franciso, CA
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
University of California at San Francisco
mi
from
San Franciso, CA
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
Children's Hospital National Medical Center
mi
from
Washington,
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
Children's Hospital National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated:  2/27/2017
University of Southern Florida College of Medicine
mi
from
Tampa, FL
Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025
Population Genetics and Immune Response to Hepatitis B Vaccination in Adolescents: A Substudy of ATN 024 and ATN 025
Status: Enrolling
Updated: 2/27/2017
University of Southern Florida College of Medicine
mi
from
Tampa, FL
Click here to add this to my saved trials
Chronic Hepatitis Intervention Project for Drug Users
Chronic Hepatitis Intervention Project for Drug Users
Status: Enrolling
Updated:  2/28/2017
RTI International Field Site
mi
from
Durham, NC
Chronic Hepatitis Intervention Project for Drug Users
Chronic Hepatitis Intervention Project for Drug Users
Status: Enrolling
Updated: 2/28/2017
RTI International Field Site
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Birmingham Gastroenterology Associates P.C.
mi
from
Birmingham, AL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Birmingham Gastroenterology Associates P.C.
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Kirklin Clinic
mi
from
Birmingham, AL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Anaheim Clinical Trials, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
VA Long Beach Healthcare System
mi
from
Long Beach, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
VA Long Beach Healthcare System
mi
from
Long Beach, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
VA Greater Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
University Of California, San Francisco/Sf General Hospital
mi
from
San Francisco, CA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
University Of California, San Francisco/Sf General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Orlando Va Medical Center
mi
from
Orlando, FL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Orlando Va Medical Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Orlando Clinical Research Center
mi
from
Orlando, FL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Infectious Disease Research Institute, Inc.
mi
from
Tampa, FL
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Infectious Disease Research Institute, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated:  3/2/2017
Gastrointestinal Specialists of Georgia
mi
from
Marietta, GA
Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Treatment With Peginterferon Alfa-2a and Ribavirin
Status: Enrolling
Updated: 3/2/2017
Gastrointestinal Specialists of Georgia
mi
from
Marietta, GA
Click here to add this to my saved trials